Defense of Mass Tort Claims, Class Actions, and Significant Product-Based Litigation
Amarin Pharma and the FDA recently announced a widely expected settlement of First Amendment litigation over restrictions on the company’s promotion of its Vascepa product.
Readers may recall that this was one of several recent challenges to the FDA’s attempt to restrict off-label promotion of prescription products, even if that speech is truthful and not…
Last week the Sixth Circuit issued a significant opinion in Yates v. Ortho-McNeil-Janssen Pharmaceuticals Inc., No. 15-3104, 2015 WL 8538119 (6th Cir.
Continue Reading Important Preemption Decision
The Food and Drug Administration has proposed to amend its regulations concerning direct-to- consumer (DTC) advertisements of prescription drugs. Spec…
Continue Reading FDA Proposes Regs on Direct-to-Consumer Prescription Drug Ads
DRI’s Drug and Medical Device Committee will hold its 26th annual Seminar on May 20-21, 2010, at the San Francisco Marriott, in San Francisco, C…
Continue Reading Upcoming Drug and Medical Device Seminar
